- Home
- BGT vs CDTX Comparison
BGT vs CDTX Comparison
Compare BGT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGT | CDTX |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 2.8B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BGT | CDTX |
|---|---|---|
| Price | $11.22 | $220.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $128.75 |
| AVG Volume (30 Days) | 107.2K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.89 | $15.22 |
| 52 Week High | $13.42 | $221.20 |
Technical Indicators
Market Signals| Indicator | BGT | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 86.62 |
| Support Level | $11.05 | $219.60 |
| Resistance Level | $11.34 | $220.38 |
| Average True Range (ATR) | 0.12 | 0.74 |
| MACD | 0.03 | -3.92 |
| Stochastic Oscillator | 54.72 | 67.82 |
Price Performance
Historical ComparisonAbout BGT BlackRock Floating Rate Income Trust
Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.